PURPOSE: To preliminarily evaluate the feasibility, therapeutic effect and toxicity of stereotactic gamma-ray body radiation therapy (γ-SBRT) for asynchronous bilateral renal cell carcinoma (bRCC). MATERIALS AND METHODS: A retrospective analysis was performed on the clinical data of nine patients with asynchronous bRCC who were unable to undergo surgery and received γ-SBRT between February 2002 and May 2012. A total dose of 36-51 Gy was delivered to the 50 % isodose line covering the planning target volume at 3-5 Gy/fraction, whereas a total dose of 60-85 Gy was delivered at 5-7 Gy/fraction to the gross target volume. The local control rate (LC) and overall survival rate (OS) were calculated using the Kaplan-Meier method. RESULTS: Patient follow-up ended in March 2013 and the follow-up rate was 100 %. Of the nine patients, none presented with complete remission and five (55.6 %) achieved partial remission. The objective response rate was 55.6 %. The 1-, 3- and 5-year LC rates were 64.8, 43.2 and 43.2 %, respectively. The 1-, 3- and 5-year OS rates were 66.7, 53.3 and 35.6 %, respectively. Four (44.4 %) patients had an acute radiation reaction; there were two cases of grade I leukocytopenia and two cases of grade I gastrointestinal reactions. Late radiation-induced toxicity consisted of grade II gastrointestinal reactions in two patients. CONCLUSION: Stereotactic gamma-ray body radiation therapy was found to be safe and effective in the treatment of asynchronous bRCC. Improved prognosis will require individualised treatment and a combination of multiple therapeutic approaches; this will be a primary research trend in the future.
PURPOSE: To preliminarily evaluate the feasibility, therapeutic effect and toxicity of stereotactic gamma-ray body radiation therapy (γ-SBRT) for asynchronous bilateral renal cell carcinoma (bRCC). MATERIALS AND METHODS: A retrospective analysis was performed on the clinical data of nine patients with asynchronous bRCC who were unable to undergo surgery and received γ-SBRT between February 2002 and May 2012. A total dose of 36-51 Gy was delivered to the 50 % isodose line covering the planning target volume at 3-5 Gy/fraction, whereas a total dose of 60-85 Gy was delivered at 5-7 Gy/fraction to the gross target volume. The local control rate (LC) and overall survival rate (OS) were calculated using the Kaplan-Meier method. RESULTS:Patient follow-up ended in March 2013 and the follow-up rate was 100 %. Of the nine patients, none presented with complete remission and five (55.6 %) achieved partial remission. The objective response rate was 55.6 %. The 1-, 3- and 5-year LC rates were 64.8, 43.2 and 43.2 %, respectively. The 1-, 3- and 5-year OS rates were 66.7, 53.3 and 35.6 %, respectively. Four (44.4 %) patients had an acute radiation reaction; there were two cases of grade I leukocytopenia and two cases of grade I gastrointestinal reactions. Late radiation-induced toxicity consisted of grade II gastrointestinal reactions in two patients. CONCLUSION: Stereotactic gamma-ray body radiation therapy was found to be safe and effective in the treatment of asynchronous bRCC. Improved prognosis will require individualised treatment and a combination of multiple therapeutic approaches; this will be a primary research trend in the future.
Authors: H Kume; H Oda; Y Nakatsuru; Y Shimizu; Y Takahashi; T Matsumoto; T Inoue; S Kameyama; T Kitamura; T Ishikawa Journal: BJU Int Date: 2000-08 Impact factor: 5.588
Authors: Michael L Blute; Nancy B Itano; John C Cheville; Amy L Weaver; Christine M Lohse; Horst Zincke Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Jeroen B Verheul; Patrick E J Hanssens; Suan Te Lie; Sieger Leenstra; Hendrik Piersma; Guus N Beute Journal: J Neurosurg Date: 2010-12 Impact factor: 5.115
Authors: Manish I Patel; Rachel Simmons; Michael W Kattan; Robert J Motzer; Victor E Reuter; Paul Russo Journal: Urology Date: 2003-05 Impact factor: 2.649
Authors: Douglas Kondziolka; Joseph G Ong; John Y K Lee; Robert Y Moore; John C Flickinger; L Dade Lunsford Journal: J Neurosurg Date: 2008-01 Impact factor: 5.115
Authors: Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo Journal: Nat Rev Urol Date: 2017-06-20 Impact factor: 14.432
Authors: Scott P Campbell; Daniel Y Song; Phillip M Pierorazio; Mohamad E Allaf; Michael A Gorin Journal: J Oncol Date: 2015-11-11 Impact factor: 4.375
Authors: Shankar Siva; Brent Chesson; Mathias Bressel; David Pryor; Braden Higgs; Hayley M Reynolds; Nicholas Hardcastle; Rebecca Montgomery; Ben Vanneste; Vincent Khoo; Jeremy Ruben; Eddie Lau; Michael S Hofman; Richard De Abreu Lourenco; Swetha Sridharan; Nicholas R Brook; Jarad Martin; Nathan Lawrentschuk; Tomas Kron; Farshad Foroudi Journal: BMC Cancer Date: 2018-10-23 Impact factor: 4.430